LIGHT (TNFSF14) enhances osteogenesis of human bone marrow-derived mesenchymal stem cells
Open Access
- 19 February 2021
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2), e0247368
- https://doi.org/10.1371/journal.pone.0247368
Abstract
Osteoporosis is a progressive systemic skeletal disease associated with decreased bone mineral density and deterioration of bone quality, and it affects millions of people worldwide. Currently, it is treated mainly using antiresorptive and osteoanabolic agents. However, these drugs have severe adverse effects. Cell replacement therapy using mesenchymal stem cells (MSCs) could serve as a treatment strategy for osteoporosis in the future. LIGHT (HVEM-L, TNFSF14, or CD258) is a member of the tumor necrosis factor superfamily. However, the effect of recombinant LIGHT (rhLIGHT) on osteogenesis in human bone marrow-derived MSCs (hBM-MSCs) is unknown. Therefore, we monitored the effects of LIGHT on osteogenesis of hBM-MSCs. Lymphotoxin-β receptor (LTβR), which is a LIGHT receptor, was constitutively expressed on the surface of hBM-MSCs. After rhLIGHT treatment, calcium and phosphate deposition in hBM-MSCs, stained by Alizarin red and von Kossa, respectively, significantly increased. We performed quantitative real-time polymerase chain reaction to examine the expressions of osteoprogenitor markers (RUNX2/CBFA1 and collagen I alpha 1) and osteoblast markers (alkaline phosphatase, osterix/Sp7, and osteocalcin) and immunoblotting to assess the underlying biological mechanisms following rhLIGHT treatment. We found that rhLIGHT treatment enhanced von Kossa- and Alizarin red-positive hBM-MSCs and induced the expression of diverse differentiation markers of osteogenesis in a dose-dependent manner. WNT/β-catenin pathway activation strongly mediated rhLIGHT-induced osteogenesis of hBM-MSCs, accelerating the differentiation of hBM-MSCs into osteocytes. In conclusion, the interaction between LIGHT and LTβR enhances osteogenesis of hBM-MSCs. Therefore, LIGHT might play an important role in stem cell therapy.Keywords
Funding Information
- National Research Foundation of Korea (NRF-2018R1D1A1B07051343)
- National Research Foundation of Korea (NRF-2017R1A1A3A04069314)
- Ulsan University Hospital (UUHBRC-2016-001)
This publication has 35 references indexed in Scilit:
- Pulp stem cells derived from human permanent and deciduous teeth: Biological characteristics and therapeutic applicationsStem Cells Translational Medicine, 2020
- miR-122 Exerts Inhibitory Effects on Osteoblast Proliferation/Differentiation in Osteoporosis by Activating the PCP4-Mediated JNK PathwayMolecular Therapy Nucleic Acids, 2020
- Retracted: MicroRNA‐539 promotes osteoblast proliferation and differentiation and osteoclast apoptosis through the AXNA‐dependent Wnt signaling pathway in osteoporotic ratsJournal of Cellular Biochemistry, 2018
- Osteoporosis: A Review of Treatment Options.2018
- Mesenchymal Stem Cells: Cell Fate Decision to Osteoblast or Adipocyte and Application in Osteoporosis TreatmentInternational Journal of Molecular Sciences, 2018
- LIGHT (TNFSF14) Increases the Survival and Proliferation of Human Bone Marrow-Derived Mesenchymal Stem CellsPLOS ONE, 2016
- Osteoporosis: the current status of mesenchymal stem cell-based therapyCellular & Molecular Biology Letters, 2016
- Mesenchymal Stem/Stromal Cells: A New "Cells as Drugs" Paradigm. Efficacy and Critical Aspects in Cell TherapyCurrent Pharmaceutical Design, 2013
- Immunosuppressive Properties of Mesenchymal Stem Cells: Advances and ApplicationsCurrent Molecular Medicine, 2012
- Mesenchymal stem cells in health and diseaseNature Reviews Immunology, 2008